Study summary

Another FcRn blocker failed to beat placebo

Rozanolixizumab phase 2 · 34 people, phase 2 · Published August 2024, Journal of Neurology, Neurosurgery and Psychiatry

-1.5point difference in disability score (not significant)

What was tested

Rozanolixizumab, a weekly FcRn-blocking injection, against placebo, after switching from immunoglobulin.

What they found

No significant difference in disability score (difference -1.5).
A high placebo stability rate may have hidden an effect.

What it means

Shows trial design matters; not every FcRn blocker has worked in CIDP.

J Neurol Neurosurg Psychiatry, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.